{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:20:16Z","timestamp":1765880416920,"version":"3.48.0"},"reference-count":60,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Celltrion Healthcare Italy S.r.l."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Plaque psoriasis is a chronic immune-mediated inflammatory disease affecting approximately 3% of the global population and resulting in a significant deterioration in quality of life. Systemic therapy with monoclonal antibodies (mAbs) targeting TNF-\u03b1, IL-23, and IL-17 improves clinical outcomes and patients\u2019 quality of life. Treatment strategies commonly include different mAbs and different sequencing approaches between agents, which are well-established in clinical practice. In contrast, evidence supporting the switch from intravenous to subcutaneous administration of the same mAb remains limited. Herein, we report data from a retrospective case series of patients with plaque psoriasis treated with intravenous infliximab (IV-IFX; Anti TNF-\u03b1) and transitioned to subcutaneous infliximab (SC-IFX) to compare clinical and patient-reported outcomes across routes. Methods: A total of 11 plaque psoriasis patients were retrospectively analyzed. The scores of the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Physician Global Assessment (PGA) were assessed during IV-IFX and after switching to SC-IFX. To evaluate patients\u2019 satisfaction, the Score of Treatment Satisfaction Questionnaire Medication-9 (TSQM-9) was evaluated. Both Student\u2019s t-test and ANOVA were used to assess statistically significant differences between the two routes of administration (p &lt; 0.05). Results: Scores for PASI, DLQI, and PGA were lower with SC-IFX compared with IV-IFX, indicating improved disease control and quality of life after the switch. PASI and DLQI improved in 81% and 100% of patients treated with SC-IFX, respectively. TSQM-9 total scores increased significantly by 24% (p &lt; 0.001). In particular, the questions addressing the \u201cconvenience\u201d of treatment revealed a marked advantage for the SC-IFX formulation (p &lt; 0.001). No treatment-emergent adverse events were registered. Conclusions: In this retrospective case series, switching from IV-IFX to SC-IFX appeared to be safe and to maintain or improve clinical response and enhanced treatment satisfaction. These findings highlight the potential of SC-IFX as a viable maintenance option for patients with plaque psoriasis previously treated with IV-IFX.<\/jats:p>","DOI":"10.3390\/jcm14248875","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:57:24Z","timestamp":1765879044000},"page":"8875","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Switching from Intravenous to Subcutaneous Infliximab in Psoriasis: A Case Series on Efficacy and Treatment Satisfaction"],"prefix":"10.3390","volume":"14","author":[{"given":"Daniele","family":"Rizzo","sequence":"first","affiliation":[{"name":"U.O.C. Dermatologia, Ospedale S. Antonio Abate, ASP Trapani, Via Cosenza, 82\u2014Casa Santa Erice, 91100 Trapani, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-1331","authenticated-orcid":false,"given":"Gaetano","family":"Licata","sequence":"additional","affiliation":[{"name":"U.O.C. Dermatologia, Ospedale S. Antonio Abate, ASP Trapani, Via Cosenza, 82\u2014Casa Santa Erice, 91100 Trapani, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Frazzitta","sequence":"additional","affiliation":[{"name":"U.O.C. Dermatologia, Ospedale S. Antonio Abate, ASP Trapani, Via Cosenza, 82\u2014Casa Santa Erice, 91100 Trapani, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Zichichi","sequence":"additional","affiliation":[{"name":"U.O.C. Dermatologia, Ospedale S. Antonio Abate, ASP Trapani, Via Cosenza, 82\u2014Casa Santa Erice, 91100 Trapani, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"ref_1","unstructured":"WHO (2025, November 01). Global Report on Psoriasis. Available online: https:\/\/www.who.int\/publications\/i\/item\/global-report-on-psoriasis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: A Brief Overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, Regional, and Worldwide Epidemiology of Psoriasis: Systematic Analysis and Modelling Study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_4","first-page":"467","article-title":"Psoriasis as a Systemic Disease","volume":"121","author":"Mrowietz","year":"2024","journal-title":"Dtsch. \u00c4rztebl. Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The Immunology of Psoriasis\u2014Current Concepts in Pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat. Rev. Dis. Primer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and Comorbid Diseases","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Orsmond, A., Bereza-Malcolm, L., Lynch, T., March, L., and Xue, M. (2021). Skin Barrier Dysregulation in Psoriasis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910841"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and Metabolic Syndrome: Implications for the Management and Treatment of Psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Petit, R.G., Cano, A., Ortiz, A., Espina, M., Prat, J., Mu\u00f1oz, M., Severino, P., Souto, E.B., Garc\u00eda, M.L., and Pujol, M. (2021). Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094983"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tokuyama, M., and Mabuchi, T. (2020). New Treatment Addressing the Pathogenesis of Psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207488"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Komiya, E., Tominaga, M., Kamata, Y., Suga, Y., and Takamori, K. (2020). Molecular and Cellular Mechanisms of Itch in Psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218406"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling Pathways and Targeted Therapies for Psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1084\/jem.20151093","article-title":"Melanocyte Antigen Triggers Autoimmunity in Human Psoriasis","volume":"212","author":"Arakawa","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA\u2013Antimicrobial Peptide Complexes Activate Human Dendritic Cells through TLR7 and TLR8","volume":"206","author":"Ganguly","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/sj.jid.5701064","article-title":"Insights into Gene Modulation by Therapeutic TNF and IFN\u03b3 Antibodies: TNF Regulates IFN\u03b3 Production by T Cells and TNF-Regulated Genes Linked to Psoriasis Transcriptome","volume":"128","author":"Haider","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19057","DOI":"10.1073\/pnas.0509736102","article-title":"Increase in TNF-\u03b1 and Inducible Nitric Oxide Synthase-Expressing Dendritic Cells in Psoriasis and Reduction with Efalizumab (Anti-CD11a)","volume":"102","author":"Lowes","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"13831","DOI":"10.1038\/s41598-017-14365-1","article-title":"IFN-\u03b3 and TNF-\u03b1 Synergism May Provide a Link between Psoriasis and Inflammatory Atherogenesis","volume":"7","author":"Mehta","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative Responses to IL-17 and TNF-\u03b1 in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis\u2014Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk Genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"EXPRESS study investigators Infliximab Induction and Maintenance Therapy for Moderate-to-Severe Psoriasis: A Phase III, Multicentre, Double-Blind Trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept Psoriasis Study Group Etanercept as Monotherapy in Patients with Psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and Safety of Ustekinumab, a Human Interleukin-12\/23 Monoclonal Antibody, in Patients with Psoriasis: 76-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus Secukinumab for the Treatment of Moderate-to-Severe Psoriasis (ECLIPSE): Results from a Phase 3, Randomised Controlled Trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French Guidelines on the Use of Systemic Treatments for Moderate-to-severe Psoriasis in Adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"ddg.13471","DOI":"10.1111\/ddg.13471","article-title":"Methods Report: Update of the German S3 Guideline for the Treatment of Psoriasis Vulgaris","volume":"16","author":"Gaskins","year":"2018","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23736\/S2784-8671.21.07132-2","article-title":"Italian Adaptation of EuroGuiDerm Guideline on the Systemic Treatment of Chronic Plaque Psoriasis","volume":"157","author":"Gisondi","year":"2022","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the Systemic Treatment of Psoriasis Vulgaris\u2014Part 1: Treatment and Monitoring Recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the Systemic Treatment of Psoriasis Vulgaris\u2014Part 2: Specific Clinical and Comorbid Situations","volume":"35","author":"Nast","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.47102\/annals-acadmedsg.2023367","article-title":"2023 Guidelines on the Management of Psoriasis by the Dermatological Society of Singapore","volume":"53","author":"Oon","year":"2024","journal-title":"Ann. Acad. Med. Singap."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e12549","DOI":"10.1111\/dth.12549","article-title":"Treatment of Psoriasis with Topical Agents: Recommendations from a Tuscany Consensus","volume":"30","author":"Chiricozzi","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gaio, M., Vastarella, M.G., Sullo, M.G., Scavone, C., Riccardi, C., Campitiello, M.R., Sportiello, L., and Rafaniello, C. (2024). Pregnancy Recommendations Solely Based on Preclinical Evidence Should Be Integrated with Real-World Evidence: A Disproportionality Analysis of Certolizumab and Other TNF-Alpha Inhibitors Used in Pregnant Patients with Psoriasis. Pharmaceuticals, 17.","DOI":"10.3390\/ph17070904"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1080\/09546634.2020.1826394","article-title":"Comparison of Psoriasis Guidelines for Use of IL-23 Inhibitors in the United States and United Kingdom: A Critical Appraisal and Comprehensive Review","volume":"33","author":"Ghamrawi","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_40","first-page":"e68569","article-title":"Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection","volume":"16","author":"Jauregui","year":"2024","journal-title":"Cureus"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1159\/000542217","article-title":"Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study","volume":"186","author":"Jeong","year":"2025","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"03000605231200270","DOI":"10.1177\/03000605231200270","article-title":"Psoriasis Paradox\u2014Infliximab-Induced Psoriasis in a Patient with Crohn\u2019s Disease: A Case Report and Mini-Review","volume":"51","author":"Mohammed","year":"2023","journal-title":"J. Int. Med. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C*06:02 Genotype Is a Predictive Biomarker of Biologic Treatment Response in Psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/1346-8138.16508","article-title":"Safety, Efficacy, and Drug Survival of the Infliximab Biosimilar CT-P13 in Post-marketing Surveillance of Japanese Patients with Psoriasis","volume":"49","author":"Morita","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e05205","DOI":"10.1002\/ccr3.5205","article-title":"Real-world Evidence for Subcutaneous Infliximab (CT-P13 SC) Treatment in Patients with Psoriatic Arthritis during the Coronavirus Disease (COVID-19) Pandemic: A Case Series","volume":"10","author":"Baraliakos","year":"2022","journal-title":"Clin. Case Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1093\/ibd\/izaf172","article-title":"When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study","volume":"31","author":"Bertani","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/apt.17822","article-title":"Long-term Effectiveness and Acceptability of Switching from Intravenous to Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease Treated with Intensified Doses: The REMSWITCH-LT Study","volume":"59","author":"Buisson","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients with Inflammatory Bowel Diseases: The REMSWITCH Study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ibd\/izad094","article-title":"One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared with Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study","volume":"30","author":"Hong","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_50","first-page":"549","article-title":"Safety and Efficacy of Transitioning Inflammatory Bowel Disease Patients from Intravenous to Subcutaneous Infliximab: A Single-Center Real-World Experience","volume":"36","author":"Jeffrey","year":"2023","journal-title":"Ann. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study","volume":"16","author":"Smith","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Viazis, N., Karamanakos, A., Mousourakis, K., Christidou, A., Fousekis, F., Mpakogiannis, K., Koukoudis, A., Katsanos, K., Christodoulou, D., and Cheila, M. (2025). Switching from Intravenous to Subcutaneous Infliximab in Patients with Immune Mediated Diseases in Clinical Remission. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1583401"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1868078","DOI":"10.1080\/19420862.2020.1868078","article-title":"Innovative Approaches to Biologic Development on the Trail of CT-P13: Biosimilars, Value-Added Medicines, and Biobetters","volume":"13","author":"Kim","year":"2021","journal-title":"mAbs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5414\/CP204388","article-title":"Subcutaneous Infliximab CT-P13 without Intravenous Induction in Psoriatic Arthritis: A Case Report and Pharmacokinetic Considerations","volume":"62","author":"Ditto","year":"2024","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jdermsci.2022.02.007","article-title":"Effectiveness of Brodalumab in Achieving Treatment Satisfaction for Patients with Plaque Psoriasis: The ProLOGUE Study","volume":"105","author":"Imafuku","year":"2022","journal-title":"J. Dermatol. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of an Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among Patients on Antihypertensive Medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/archdermatol.2010.384","article-title":"Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: Efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial","volume":"147","author":"Leonardi","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/apt.70267","article-title":"Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease","volume":"62","author":"Chetwood","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized Controlled Trial: Subcutaneous vs. Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/ibd\/izaf038","article-title":"Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies","volume":"31","author":"Schreiber","year":"2025","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8875\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:16:05Z","timestamp":1765880165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":60,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14248875"],"URL":"https:\/\/doi.org\/10.3390\/jcm14248875","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}